The emergence of the circadian clock network in hiPSC-derived hepatocytes on chip

Gagliano, Onelia; Cascione, Sara; Michielin, Federica; Elvassore, Nicola

doi:10.1016/j.bbrc.2022.02.046

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, cells derived from iPSCs are not entirely consistent with native liver cells, and their structure and function are immature [102]. Although it is a good idea to use relatively simple models to study complex phenomena and problems, there is still much room for improving the physiological relevance of models [103].…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery

Qiu

Tan

2023

Pharmaceutics

View full text Add to dashboard Cite

Drug discovery is an expensive, long, and complex process, usually with a high degree of uncertainty. In order to improve the efficiency of drug development, effective methods are demanded to screen lead molecules and eliminate toxic compounds in the preclinical pipeline. Drug metabolism is crucial in determining the efficacy and potential side effects, mainly in the liver. Recently, the liver-on-a-chip (LoC) platform based on microfluidic technology has attracted widespread attention. LoC systems can be applied to predict drug metabolism and hepatotoxicity or to investigate PK/PD (pharmacokinetics/pharmacodynamics) performance when combined with other artificial organ-on-chips. This review discusses the liver physiological microenvironment simulated by LoC, especially the cell compositions and roles. We summarize the current methods of constructing LoC and the pharmacological and toxicological application of LoC in preclinical research. In conclusion, we also discussed the limitations of LoC in drug discovery and proposed a direction for improvement, which may provide an agenda for further research.

show abstract

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery

Qiu

Tan

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Liver-on-a-chip devices: the pros and cons of complexity

Dalsbecker

Adiels

Goksör

2022

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Physiologically relevant and broadly applicable liver cell culture platforms are of great importance in both drug development and disease modeling. Organ-on-a-chip systems offer a promising alternative to conventional, static 2D cultures, providing much-needed cues such as perfusion, shear stress and 3D cell-cell communication. However, such devices cover a broad range of complexity both in manufacture and in implementation. In this review, we summarize the key features of the human liver that should be reflected in a physiologically relevant liver-on-a-chip model. We also discuss different material properties of importance in producing liver-on-a-chip devices, and summarize recent and current progress in the field, highlighting different types of devices at different levels of complexity.

show abstract

The emergence of the circadian clock network in hiPSC-derived hepatocytes on chip

Cited by 2 publications

References 23 publications

Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery

Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery

Liver-on-a-chip devices: the pros and cons of complexity

Contact Info

Product

Resources

About